Results 41 to 50 of about 55,614 (218)

Clarithromycin Resistance in Helicobacter Pylori

Central Asian Journal of Medical Sciences, 2016
Objectives: Eradication rates of Helicobacter pylori with standard triple therapy are disappointing in studies from several countries. The main reason for failure was found to be bacterial resistance to one of the most commonly used antibiotics ...
Mandkhai Bolor-Erdene, Bira Namdag, Sarantuya Jav   +2 more
doaj   +1 more source

Clarithromycin-resistant Helicobacter pylori in Recife, Brazil, directly identified from gastric biopsies by polymerase chain reaction

Arquivos de Gastroenterologia, 2010
CONTEXT: Clarithromycin is the most effective drug used in the eradication of infection by Helicobacter pylori. Due to worldwide increase in resistance, pre-treatment susceptibility testing for clarithromycin is recommended.
Ana Kelly Lins, Roberto A Lima, Marcelo Magalhães   +2 more
doaj   +1 more source

Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The study aims to develop a physiologically‐based pharmacokinetic (PBPK) model to quantitatively evaluate the role of ATP‐binding cassette sub‐family B member 1 (ABCB1) and ATP‐binding cassette super‐family G member 2 (ABCG2) in the drug–drug interaction (DDI) between rifampin and linezolid and to predict the impact of high‐dose rifampin ...
Hoang Dat Nguyen, Vinh Hoa Pham, Richard M. Hoglund, Joel Tarning, Junjie Ding   +4 more
wiley   +1 more source

Assessment and analysis of H.pylori infection treatment strategies of St. Vincent Hospital\u27s family and internal medicine clinics [PDF]

, 2019
Helicobacter pylori is a gram-negative bacteria that is responsible for causing chronic gastritis, ulcers in the stomach and intestine, and eventually even gastric lymphoma or cancer.
Orr, Rebecca
core   +1 more source

New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]

, 2017
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core   +1 more source

Inflammation‐driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited.
Sylvia D. Klomp, Martijn L. Manson, Henk‐Jan Guchelaar, Stefan Böhringer, Esther H. M. van Egmond, Peter A. von dem Borne, Jesse J. Swen   +6 more
wiley   +1 more source

Short Course Monotherapy with Clarithromycin for Localized Mycobacterium Marinum Skin Infection

Canadian Journal of Infectious Diseases, 1997
In vitro studies have shown that Mycobacterium marinum is usually susceptible to clarithromycin. However, there are limited published data on the clinical use of clarithromycin for the treatment of M marinum infections. This report describes a previously
Mitchell R Weinstein, Donald E Low, Tony Mazzulli   +2 more
doaj   +1 more source

Identification of New Drug Candidates Against \u3cem\u3eBorrelia burgdorferi\u3c/em\u3e Using High-Throughput Screening [PDF]

, 2016
Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that .300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of
Babar, Mustafeez Mujtaba, Inayathullah, Mohammed, Kim, K. M., Parekh, Mansi B., Pothineni, Venkata Raveendra, Rajadas, Jayakumar, Samineni, A. V., Solow-Cordero, David, Tayebi, Lobat, Wagh, Dhananjay   +9 more
core   +3 more sources

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh, Kate Hanrott, Olof Breuer, Johan Bylund, Björn Schultze, Virginia Norris   +5 more
wiley   +1 more source

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed nonsteroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known off‐target polypharmacology. Methods Physicochemical and polypharmacology data were curated from the Electronic Medicines Compendium ...
Simrit Dhillon, Albert A. Antolin, Alan M. Jones   +2 more
wiley   +1 more source